ストックスクリーナーアプリを入手
0.3373
5.78%
0.0171
前日終値:
$0.3202
開ける：
$0.3418
24時間の取引高:
5.23M
Relative Volume:
2.87
時価総額：
$21.77M
収益：
-
当期純損益:
$-123.46M
株価収益率:
-0.1302
EPS:
-2.59
ネットキャッシュフロー:
$-104.11M
1週間 パフォーマンス:
+5.12%
1か月 パフォーマンス:
-49.46%
6か月 パフォーマンス:
-15.28%
1年 パフォーマンス:
-31.52%
1日の値動き範囲:
$0.3268
$0.385
1週間の範囲:
$0.29
$0.385
52週間の値動き範囲:
$0.2601
$1.43
Bioatla Inc Stock (BCAB) Company Profile
BCAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.34 | 20.51M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.84 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.20 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
825.34 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.46 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.86 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | 開始されました | Rodman & Renshaw | Buy |
| 2025-08-13 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-05-05 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-06-28 | 開始されました | ROTH Capital | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | BTIG Research | Buy |
| 2021-01-11 | 開始されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | JP Morgan | Overweight |
| 2021-01-11 | 開始されました | Jefferies | Buy |
すべてを表示
Bioatla Inc (BCAB) 最新ニュース
Aug Chart Watch: What is the dividend yield of BioAtla IncWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Whale Trades: Is BioAtla Inc forming bullish engulfing patternsJuly 2025 Price Swings & Risk Controlled Daily Plans - baoquankhu1.vn
What analysts say about BioAtla Inc. stockTrade Risk Assessment & Free Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
Aug Decliners: Can BioAtla Inc deliver consistent dividendsEarnings Overview Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Big Money Moves: Should you buy the dip on BioAtla IncJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00 - Defense World
BioAtla faces Nasdaq delisting over share price rule - MSN
BioAtla (NASDAQ:BCAB) Coverage Initiated by Analysts at Rodman & Renshaw - Defense World
VIX Spike: Can BioAtla Inc deliver consistent dividendsJuly 2025 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
BioAtla Creates Super-Voting Share to Advance Reverse Split - The Globe and Mail
BioAtla stock initiated with Buy rating at Rodman & Renshaw - Investing.com
Why BioAtla Inc. stock remains resilientJuly 2025 Gainers & Real-Time Buy Signal Notifications - Улправда
BioAtla, Inc.Common Stock (NQ: BCAB - FinancialContent
Is BioAtla Inc. stock undervalued vs historical averages2025 Big Picture & Consistent Growth Stock Picks - ulpravda.ru
Is BioAtla Inc. stock attractive for hedge funds2025 Volatility Report & Daily Stock Trend Reports - Улправда
Is BioAtla Inc. stock dividend yield sustainable2025 Stock Rankings & Entry Point Confirmation Alerts - Улправда
What risks investors should watch in BioAtla Inc. stockEarnings Risk Report & Fast Entry Momentum Trade Alerts - Улправда
How BioAtla Inc. stock performs in rising dollar environmentMarket Volume Summary & Short-Term Trading Alerts - Улправда
How rising interest rates impact BioAtla Inc. stock2025 EndofYear Setup & Free Community Consensus Stock Picks - ulpravda.ru
Will BioAtla Inc. stock maintain momentum in 2025Volatility Index Analysis & Low Cost Portfolio Growth - ulpravda.ru
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla, GATC Health Advance Ozuriftamab Vedotin Into Phase 3 OPSCC Trial Via SPV Deal - Voice Of HealthCare
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Asianet Newsable
BioAtla’s Phase 3 Cancer Trial Is “AI-Backed”. Just Not in the Way You Think - AIM Media House
BioAtla and GATC Health to advance Oz-V in Phase III trial - Yahoo Finance
BioAtla announces $40 million oncology SPV investment deal - MSN
Bioatla stock rises after $40 million SPV deal to advance cancer drug - Investing.com Australia
BioAtla secures $40 million for phase 3 cancer drug development By Investing.com - Investing.com Nigeria
BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V - parameter.io
Bioatla stock rises after $40 million SPV deal to advance cancer drug By Investing.com - Investing.com South Africa
BioAtla Announces $40 Million Oncology SPV Investment Deal - TipRanks
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma - Investing News Network
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
BioAtla secures $40 million for phase 3 cancer drug development - Investing.com India
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - The Manila Times
BioAtla Secures $5 Million Initial Funding for Phase 3 Trial of Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma - Quiver Quantitative
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Bioatla Inc (BCAB) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.08%
大文字化:
|
ボリューム (24 時間):